Precise regulation of transcription is crucial for the cellular mechanisms underlying memory formation. However, the link between neuronal stimulation and the proteins that directly interact with histone modifications to activate transcription in neurons remains unclear. Brd4 is a member of the bromodomain and extra-terminal domain (BET) protein family, which binds acetylated histones and is a critical regulator of transcription in many cell types, including transcription in response to external cues. Small molecule BET inhibitors are in clinical trials, yet almost nothing is known about Brd4 function in the brain. Here we show that Brd4 mediates the transcriptional regulation underlying learning and memory. The loss of Brd4 function affects critical synaptic proteins, which results in memory deficits in mice but also decreases seizure susceptibility. Thus Brd4 provides a critical link between neuronal activation and the transcriptional responses that occur during memory formation. npg 1 4 6 5 a r t I C l e S b Brd4 NeuN DAPI
a r t I C l e S The nervous system requires tight control of transcription in response to external signals. Rapid activation of immediate early genes (IEGs) in response to stimulation is critical for synaptic plasticity and is observed in vivo during learning and memory. Misregulation of gene expression in the brain results in neuronal deficits and neurodevelopmental disorders 1, 2 , and inhibition of transcription immediately after neuronal stimulation blocks the mechanisms underlying memory formation [3] [4] [5] [6] . This inducible transcription requires that transcriptional activators bind to promoters of target genes and recruit other proteins such as RNA polymerase II (PolII) 7, 8 . Recent work found that, in several non-neuronal cell types, the protein Brd4 is critical in regulating the recruitment of protein complexes such as positive transcription elongation factor b (P-TEFb) to allow PolII phosphorylation and the subsequent elongation of target genes in response to a signal 9-12 . Brd4 is a member of the BET protein family and functions as a chromatin 'reader' that binds acetylated lysines in histones 13, 14 . Knockout of Brd4 in mice is lethal 15 , and recent elegant work indicates that small molecule inhibitors of BET proteins represent a promising therapeutic strategy for several types of cancer [16] [17] [18] . Brd4 also regulates stimulusdependent transcription in postmitotic cells by recruiting P-TEFb to target promoters in response to extracellular signals 13, 19 . While P-TEFb recruitment is necessary for transcriptional elongation in neurons 20 , the link between neuronal stimulation and the proteins that directly interact with histone modifications to activate transcription remains unclear.
Brd4 is well positioned to regulate transcription in neurons in response to neuronal activation. Acetyl marks are critical to brain function and are linked to memory formation and neurological disorders 21 . Brd4 activity is regulated by casein kinase 2 (CK2) 14 , which is activated in response to neuronal stimulation 22 . In addition, a full understanding of whether and how Brd4 functions in the brain is of particular importance now because BET protein inhibitors are in clinical trials.
Here we show that Brd4 is critical to neuronal function and mediates the transcriptional regulation underlying learning and memory. We found that Brd4 regulates IEG transcription in neurons in response to activity and is regulated by CK2. Loss of Brd4 function affects critical synaptic proteins and the BET inhibitor Jq1 results in memory deficits and decreases seizure susceptibility in mice. These results are, to our knowledge, the first demonstration of Brd4 function in the brain and provide a critical link between neuronal activity and transcriptional activation that underlies memory formation. In addition, our data call attention to the potential for small molecule inhibitors of BET proteins such as Jq1 to cause neuronal deficits. While BET protein inhibitors are a promising therapeutic strategy for several types of cancer 17, 18, [23] [24] [25] , modifications preventing blood-brain barrier penetrability may be necessary to prevent neurological side effects.
RESULTS

Brd4 is expressed in neurons
We examined Brd4 expression in adult mice using an antibody that detects the full-length form of Brd4 and found that it was expressed throughout the brain ( Fig. 1a and Supplementary Fig. 1a ). Brd4 positive cells typically expressed NeuN but not GFAP in both cortex and hippocampus ( Fig. 1b-i) , indicating that Brd4 is present in neurons while generally not seen in glial cells. In addition, we separately cultured cortical neurons and glia and found that neurons contained more Brd4 mRNA and protein than glial cells (Fig. 1j,k) . Both CamKII-positive excitatory neurons and GABA-positive inhibitory neurons expressed Brd4 (Supplementary Fig. 1b,c) . Finally, we treated cultured neurons with brain-derived neurotrophic factor (BDNF) to mimic physiological activation in the brain 6 , which resulted in small increases in Brd4 mRNA and protein ( Supplementary Fig. 1d-f Supplementary Figure 10 . In box plots, whiskers show minimum and maximum, box limits are first and third quartile, and center line is median. DAPI, 4′,6-diamidino-2-phenylindole. ***P < 0.001. Scale bars, 1 mm (a) and 10 µm (b-i). npg a r t I C l e S However, pretreatment with Jq1 blocked the BDNF-induced increase (Fig. 2b,c) . Rapidly induced IEGs such as Arc and Fos have PolII poised on their promoters to allow immediate activation, while other IEGs such as Nr4a1 must both recruit and phosphorylate PolII to activate transcription 20 . We found that Jq1 also prevented the activity-induced increase of Nr4a1 (Fig. 2d) , indicating that Jq1's affects are not limited to IEGs with poised PolII.
We similarly examined the effects of Jq1 on tetrodotoxin (TTX) withdrawal which rapidly increases neuronal activity. Neurons were treated with TTX for 2 d, after which Jq1 or the negative enantiomer was added before TTX was removed from the medium. Jq1
Brd4 regulates IEG transcription in neurons
Like other post-mitotic cells that require Brd4 (refs. 13,19) , neurons activate a subset of genes (IEGs) in response to external signals. This rapid response is critical to the consolidation of synaptic modifications underlying synaptic plasticity and memory formation [3] [4] [5] [6] . We examined whether Brd4 is involved in transcriptional activation in neurons using the small molecule inhibitor Jq1, which blocks BET proteins from binding to acetylated histones 18 . After pretreatment with Jq1 or the negative enantiomer (-)Jq1, we stimulated cultured cortical neurons with BDNF ( Fig. 2a) . As expected, BDNF caused a rapid increase in transcripts of the IEGs Arc and Fos. , Fos (c) and Nr4a1 (d) RNAs in cultured cortical neurons in response to 10 min of BDNF stimulation (n = 14 biological replicates, paired two-tailed t test for Arc P = 0.0014, t = 3.133; for Fos P = 1.86 × 10 −5 , t = 4.064; for Nr4a1 P = 0.0178, t = 2.53). (e-g) Jq1 pretreatment blocks the increase in nascent Arc (e), Fos (f) and Nr4a1 (g) RNAs in cultured cortical neurons 10 min after TTX withdrawal (paired two-tailed t test, for Arc n = 7, P = 0.0186, t = 2.475; for Fos n = 8, p = 0.0264, t = 2.1998; for Nr4a1 n = 4, p = 0.0406, t = 2.456). (h-j) Infection of neurons with a Brd4 siRNA lentivirus, but not a scrambled control virus, blocks Arc (h), Fos (i) and Nr4a1 (j) induction in response to 10 min of BDNF stimulation (n = 6 biological replicates, paired two-tailed t test, for Arc P = 0.0337, t = 2.502; for Fos P = 0.0450, t = 2.327; for Nr4a1 P = 0.0311, t = 2.551). (k,l) Staining (k) and quantification (l) of Arc in neurons stimulated for 30 min with BDNF following pretreatment with Jq1 or the negative enantiomer (-)Jq1 (unpaired two-tailed t test, for control n = 232 neurons, for BDNF n = 185, for Jq1 n = 245 and for Jq1 + BDNF n = 200 from 5 biological replicates per group; for control versus BDNF P = 8.52 × 10 −26 , t = 11.447; Jq1 versus Jq1 + BDNF P = 0.00084, t = 3.363; for BDNF versus Jq1 + BDNF P = 0.00013, t = 3.867). (m,n) Quantification (m) and staining (n) for Arc in neurons transfected with GFP and either a nontargeting siRNA pool or Brd4 siRNA (unpaired two-tailed t test, for control n = 105 neurons, for BDNF n = 80, for Brd2 siRNA n = 85, for Brd2 + BDNF n = 71, for Brd3 n = 88, for Brd3 + BDNF n = 63, for Brd4 n = 80 and for Brd4 + BDNF n = 71 from 11 biological replicates; for control versus BDNF P = 0.0012, t = 3.296; for Brd4 siRNA versus Brd4 siRNA + BDNF P = 0.662, t = 0.438; for Brd2 siRNA versus Brd2 siRNA + BDNF P = 8.572 × 10 −5 , t a r t I C l e S again prevented rapid IEG induction ( Fig. 2e-g) . Notably, Jq1 could not prevent IEG activation after long periods of BDNF stimulation (Supplementary Fig. 2a-c ), suggesting that Jq1 only affects the rapid increase in transcription, whereas at later times signaling may be robust enough to overcome BET inhibition. Because Jq1 also inhibits other members of the BET protein family, we tested whether loss of Brd4 is sufficient to block IEG induction. Partial knockdown of Brd4 with a lentivirus also blocked BDNF-induced IEG expression but did not block upstream pathways such as mitogen-activated protein kinase (MAPK) signaling ( Fig. 2h-j and Supplementary Fig. 2d,e ). These data fit with a model similar to that observed in other cell types, in which Brd4 recruits P-TEFb to promote PolII phosphorylation to allow rapid transcriptional elongation.
To confirm that the loss of transcriptional activation results in a corresponding change in protein levels, we examined Arc protein expression at 30 min, when newly transcribed mRNA has been translated into protein. As expected, Jq1-treated neurons showed less Arc protein induction than control neurons ( Fig. 2k,l) . Similarly, transfection of small interfering RNAs targeted against Brd4 blocked the BDNF-induced increase in Arc protein, whereas transfection with nontargeting siRNA or siRNAs targeted against the other BET family members did not ( Fig. 2m,n and Supplementary Fig. 2f- 
i).
BrdT is testes-specific, and so we did not test it. To ensure that the loss of Arc induction was not due to off-target effects, we tested two distinct Brd4 siRNAs. These also blocked BDNF-induced Arc expression ( Supplementary Fig. 2j-l) .
Finally, we sought to determine which of Brd4's known functions is responsible for its effects in neurons. Full-length Brd4 can function by recruiting complexes such as pTEFb and Mediator to trigger elongation, whereas both the long and short forms of Brd4 can promote PolII progression through acetylated nucleosomes after elongation begins 26 . We found that only the long form of Brd4 affects Arc expression ( Supplementary Fig. 2m ), indicating that Brd4 is likely functioning in neurons by recruiting coactivating complexes to target genes.
These data demonstrate that Brd4 regulates activity-induced IEG expression in neurons. However, inhibition of Brd4 may also disrupt transcriptional output in neurons even without a potent stimulus such as BDNF as a result of the cumulative loss of the response to endogenous signaling from other neurons over a long period of time. Indeed, we found that, by 24 h, Jq1 decreased Arc, Fos and Nr4a1 transcripts ( Supplementary Fig. 2n ). We also confirmed that long-term disruption of this BET function did not cause widespread disruption of chromatin acetylation ( Supplementary Fig. 2o ), as expected from its function as reader protein. Finally, we showed that Jq1 did not block upstream signaling pathways by demonstrating that MAPK phosphorylation is intact ( Supplementary Fig. 2p ). Together, these data demonstrate that Brd4 is responsible for transcription of IEGs in neurons.
Genome-wide effects of Jq1
While Brd4 clearly regulates specific IEGs, inhibition of Brd4 likely also affects a wider range of genes. We used RNA-sequencing to examine BDNF induction of IEGs after Jq1 treatment and long-term effects of Jq1. An extended pretreatment of Jq1 followed by BDNF stimulation (Supplementary Fig. 3a ) recapitulated the effects of Jq1 on induction of the specific IEGs previously examined but did not affect the housekeeping gene Gapdh (Fig. 3a) . We expanded this comparison to all genes significantly induced by BDNF and found a consistent decrease in induction in the presence of Jq1 ( Fig. 3b and Supplementary  Fig. 3b ), supporting a model in which Brd4 mediates the rapid response to neuronal activity. In addition, we also examined the effects of 24 h of Jq1 treatment in the absence of exogenous stimulation. At this later time point, the effects of the loss of IEG transcription in response to basal levels of endogenous neuronal signaling will be apparent. We found a highly significant overlap between BDNFinduced genes and those regulated by Jq1 alone (P < 0.000005, paired two-tailed t-test). We also separately examined genes up-and downregulated by Jq1, as downregulated genes are more likely to be direct targets of Brd4 as a result of its function as a transcriptional activator. Gene clusters most significantly downregulated by Jq1 included genes involved synapse function ( Fig. 3c ) and ion channel function ( Fig. 3d ). Jq1 treatment also increased genes involved in chromatin regulation and genes encoding nuclear proteins ( Supplementary  Fig. 3c ). Such increases may be compensatory effects or indirect effects resulting from decreases in Brd4 target genes. To determine which histone modifications are responsible for recruiting Brd4 to target genes, we examined known Brd4 target acetyl marks and found that BDNF increased H3K14 and H4K16 acetylation at IEG promoters ( Supplementary Fig. 3d ), suggesting they may be involved in the stimulus-dependent recruitment of Brd4. As expected, Jq1 did not affect these marks (Supplementary Fig. 3e ). 
Brd4 is regulated by CK2 in neurons
To better understand how Brd4 is targeted to chromatin in neurons, we next examined the mechanism underlying activation of Brd4 itself. We found that BDNF stimulation increased Brd4 association with promoter regions of IEGs, suggesting that neuronal activity targets Brd4 to acetylated histones immediately after stimulation (Supplementary Fig. 4a-c) . This effect was not observed for Brd2 or Brd3 ( Supplementary  Fig. 4d-i) . To investigate how Brd4 is targeted to promoters, we explored the role of CK2. In the human embryonic kidney (HEK) 293 cell line, CK2 phosphorylates Brd4, which triggers Brd4 binding to acetylated histones at target gene promoters to activate transcription 14 . In neurons, CK2 is important in regulating synaptic strength 27, 28 and is activated by BDNF stimulation 22 . We found that BDNF-induced targeting of Brd4 was blocked by pretreatment with the CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB), as well as Jq1 (Fig. 4a-c) , suggesting that Brd4 is activated by CK2 in response to neuronal activity. This short TBB pretreatment did not prevent MAPK phosphorylation, demonstrating upstream signaling is intact (Supplementary Fig. 4j ). Neither TBB nor Jq1 prevented BDNF-induced CREB binding protein (CBP) association with chromatin, indicating that other transcriptional cofactors are still recruited to target genes ( Supplementary Fig. 4k-m) . If Brd4 activation by CK2 is necessary for the activity-dependent transcription, then CK2 inhibition should also block the activity-induced increase in IEGs. Fitting with this model, pretreatment with TBB blocked the increase in Arc, Fos and Nr4a1 mRNA ( Fig. 4d-i) , as well as Arc protein levels ( Fig. 4j-k) . To control for off-target effects of TBB, we confirmed that transfection of Csnk2a1 (Ck2) siRNA also blocked Arc protein induction ( Supplementary Fig. 4n-p) . (a-c) Brd4 ChIP-quantitative PCR analysis in cultured neurons pretreated with vehicle or CK2 inhibitor TBB and stimulated with BDNF for 10 min to measure Brd4 at promoters of Arc (a), Fos (b) and Nr4a1 (c) (paired two-tailed t test, for Arc DMSO treatments n = 10 biological replicates, P = 0.00955, t = 1.693; for TBB treatments n = 6 and for Jq1 n = 3; for Fos n = 8 biological replicates, P = 0.0303, t = 2.791; for TBB n = 6 and for Jq1 treatments n = 3; for Nr4a1 DMSO treatments n = 9 biological replicates, P = 0.0411, t = 1.987; for TBB treatments n = 5 and for Jq1 n = 3). (d-f) TBB pretreatment blocks increases in Arc (d), Fos (e) and Nr4a1 (f) mRNA after 10 min BDNF stimulation (paired two-tailed t test, for Arc n = 14 biological replicates, P = 0.0215, t = 2.505; for Fos n = 14, P = 0.0175, t = 2.496; and for Nr4a1 n = 13, P = 0.0122, t = 2.926). (g-i) TBB pretreatment blocks increases in Arc (g), Fos (h) and Nr4a1 (i) mRNA 10 min after TTX withdrawal (paired two-tailed t test, for Arc n = 8 biological replicates, P = 0.0451, t = 2.485; for Fos n = 8, P = 0.0179, t = 2.728; and for Nr4a1 n = 6, P = 0.0437, t = 2.983). (j,k) Arc and Brd4 staining (j) and quantification (k) after TBB or vehicle pretreatment and 30-min BDNF stimulation (unpaired two-tailed t test, for control n = 108 neurons, for BDNF n = 131, for TBB n = 117, for TBB + BDNF n = 118 from 2 biological replicates; for control versus BDNF P = 7.42 × 10 −14 , t = 7.962; for TBB versus TBB + BDNF P = 0.001, t = 3.331; for BDNF versus TBB + BDNF P = 7.598 × 10 −10 , t = 6.408). (b) Western blot for phosphorylated Brd4 (pBrd4) shows an increase with BDNF but not after TBB pretreatment or phosphatase treatment of lysates. Representative of 3 biological replicates. (c,d) Staining (c) and quantification (d) for Arc and Brd4 in neurons transfected with GFP and Brd4 bearing deletions or mutations in the CK2 site (unpaired two-tailed t test, for GFP n = 68, for Brd4 n = 61, for CK2 deletion n = 46, for deletion 492-494 n = 44, for S492A n = 54, for Brd4-pm n = 51 from 5 biological replicates; for GFP versus Brd4 P = 1.223 × 10 −8 , t = 6.09; for GFP versus Brd4-pm P = 2.00 × 10 −13 , t = 2.353; for Brd4 versus CK2 deletion P = 0.0011, t = 3.36; for Brd4 versus deletion 492-494 P = 0.00037, t = 3.689, for Brd4 versus S492A P = 0.0075, t = 2.724; for Brd4 versus Brd4-pm P = 0.0204, t = 2.353). (e) Quantification of the mobile fraction from FRAP performed on Brd4 with mutations in the CK2 domain (unpaired twotailed t test, for Brd4 n = 57 neurons, for S492A n = 52 and for Brd4-pm n = 38 from 3 biological replicates; for Brd4 versus S492A P = 0.0001, t = 4.042; for Brd4 versus Brd4-pm P = 0.0085, t = 2.488). (f) Pearson correlation coefficient for H4K16ac colocalization with Brd4 with CK2 site mutations (two-sided, two-tailed t test for Brd4 n = 35 neurons, for Brd4 + BDNF n = 21, for S492A n = 29 and for Brd4-pm n = 18 from 3 biological replicates; for Brd4 versus Brd4 + BDNF P = 0.0164, t = 2.477, for Brd4 versus S492A P = 0.00167, t = 3.286; for Brd4 versus S492A P = 0.035, t = 2.166). *P < 0.05. ***P < 0.001. a.u., arbitrary units; p'ase, phosphatase. Full-length blots are presented in Supplementary Figure 11 . Error bars represent s.e.m. Scale bar, 10 µm. To further support our proposed mechanism of Brd4phosphorylation-induced chromatin targeting, we examined the movement of Brd4 after neuronal stimulation using fluorescence recovery after photobleaching (FRAP). Using live neurons, we photobleached a region of the nucleus of expressing EGFP-Brd4 and observed the recovery of the signal in the bleached region over time to measure the mobile fraction of Brd4. As expected, Jq1 increased the mobile fraction (Supplementary Fig. 4q) . The mobile fraction of Brd4 also increased after BDNF treatment, presumably as it is activated and relocates to acetylated chromatin. However, the enhanced mobility of Brd4 was blocked by TBB ( Fig. 4l-n) , indicating that CK2 is responsible for this effect.
To better understand the mechanism of Brd4 activation in neurons, we examined the specific serine residues in the CK2 site in Brd4, Ser492 and Ser494, that are critical to Brd4 activation 14 (Fig. 5a) . We developed a site-selective antibody against a peptide containing the Brd4 CK2 site with phosphorylated Ser492. Using a dot blot assay, we found that the affinity-purified antibody specifically bound a peptide phosphorylated at Ser492, as well as a peptide phosphorylated at both Ser492 and Ser494, but did not recognize the unphosphorylated peptide (Supplementary Fig. 5a ). Next we used neuronal lysates to determine the specificity of the antibody in cells by western blot and observed a band matching the size of full-length Brd4 that was not present in lysates treated with phosphatase, although other low-molecular-weight bands were also observed at high exposures (Supplementary Fig. 5b) . We observed a robust BDNF-induced increase in the phospho-Brd4 signal that was lost with TBB pretreatment (Fig. 5b) .
Next, to ensure that the effects of CK2 inhibition and knockdown were due to its effects on Brd4 and not an indirect effect of other CK2 targets, we tested the critical target residues in the CK2 phosphorylation site in Brd4. We created a full deletion (delCK2) and partial deletion (del492-494) and a point mutation (S492A) in the CK2 site in Brd4. Transfection of wild-type Brd4 increased Arc expression even in the absence of exogenous stimulation. However, this effect was greatly reduced when the CK2 site was mutated or deleted. Conversely, phosphomimetic (Brd4-pm) mutations at the key serines in Brd4 (S492E and S494E) resulted in an even greater increase in Arc expression ( Fig. 5c,d) . This demonstrates that phosphorylation of the CK2 site in Brd4 is necessary for its ability to activate transcription of Arc. We also repeated our FRAP assay and found the S492A mutant decreased Brd4 mobility, presumably by preventing activation of Brd4 from endogenous signaling, while the phosphomimetic Brd4 behaved similarly to BDNF-stimulated Brd4, showing an increased mobile fraction ( Fig. 5e) . Finally, we sought to confirm that this increase in the mobile fraction corresponded to a translocation to active chromatin. We focused on acetylated H4K16, which recruits Brd4 and increases in response to BDNF (Supplementary Fig. 3d ). We found moderate colocalization of H4K16ac and wild-type Brd4 under basal conditions that was enhanced with BDNF stimulation as expected. We then tested the phosphomutant and phosphomimetic forms of Brd4 and determined that the S492A mutation decreased H4K16ac colocalization while Brd4-pm mutations increased colocalization, as measured by Pearson's coefficient ( Fig. 5f and Supplementary Fig. 5d-e) . Together, these data support a model in which CK2 phosphorylates Brd4 in response to neuronal activity, resulting in Brd4 binding to target promoter regions and increased transcription of target IEGs.
Brd4 affects neuronal receptor proteins
In neurons, IEGs regulate the response to activity by changing the receptor content of synapses both by directly modifying synaptic npg a r t I C l e S Figure 6 Brd4 regulates synaptic receptor subunit GluA1. (a) Jq1 treatment for 24 h decreases Gria1 but not Gria2 mRNA in the absence of exogenous stimulation in cultured cortical neurons. (one-sample t test, for Gria1 n = 12 biological replicates, P = 6.852 × 10 −6 , t = 7.959; for Gria2 n = 6 biological replicates). proteins and altering gene expression of these proteins 29, 30 . Thus, the prolonged loss of IEG activation resulting from Jq1 treatment may affect neuronal function by changing critical synaptic proteins. In addition, RNA-sequencing data suggest that Jq1 treatment affects transcription of synaptic proteins and receptors in neurons ( Fig. 3c,d) . We therefore examined the GluA1 subunit of the AMPA receptor (AMPAR), the main excitatory receptor in neurons. Jq1 treatment decreased transcript levels of Gria1 (Fig. 6a) , the gene encoding GluA1, and decreased total GluA1 protein ( Fig. 6b) . Jq1 did not affect Gria2, which, unlike Gria1, lacks activity-responsive promoter regions 31, 32 . These changes, as well as those observed on IEGs, occurred slowly, over the course of several hours of Jq1 treatment (Supplementary Fig. 6a ). To confirm that decreasing the total pool of available GluA1 results in decreased surface expression, we used a surface-staining assay that specifically stains receptors expressed on the exterior of dendrites. We found that both Jq1 and Brd4 siRNA, but not Brd2 or Brd3 siRNA, decreased GluA1 surface expression in both cortical and hippocampal neurons without affecting spine number (Fig. 6c-g and Supplementary  Fig. 6b-e ). Increasing Brd4 expression resulted in a small, but significant, increase in GluA1 surface expression ( Fig. 6g-i) . We again compared the long and short forms of Brd4 and found that full-length Brd4 increased GluA1 surface expression while the short isoform did not (Supplementary Fig. 6f) , indicating that Brd4 functions by recruiting coactivating complexes to the promoter of target genes. Gria1 may be a direct target of Brd4, as Brd4 chromatin immunoprecipitation (ChIP) assays showed a high basal level of Brd4 at Gria1 regulatory elements in the promoter region and the small BDNF-induced increase in Brd4 binding is not seen with Jq1 (Supplementary Fig. 6g ). In addition, we observed a nonsignificant increase in histone acetyl marks at the Gria1 promoter following BDNF treatment (Supplementary Fig. 6h) . These data provide support for RNA-sequencing data showing that Jq1 affects synaptic proteins and demonstrate that Brd4 affects the expression of a critical subunit of a major excitatory receptor in neurons.
Jq1 treatment affects memory formation
Because of the importance of Brd4 in controlling critical neuronal proteins, we examined whether Jq1 affects brain function in mice. We injected wild-type adult male mice with Jq1 (50 mg/kg) daily for 1 week or 3 weeks before performing behavioral tests. Jq1 has excellent blood-brain barrier permeability 33 , and, as in previous reports, we found that Jq1 was well tolerated in mice at this dose and schedule 17, 18, 22, 23 (Supplementary Fig. 7a) . In an open field test, Jq1 did not affect distance traveled or zone preference, indicating that Jq1 does not cause anxiety or problems with mobility ( Fig. 7a and  Supplementary Fig. 7b-d) .
We next used a novel object-recognition task (Fig. 7b) in which mice were briefly exposed to two identical objects and later presented with one familiar and one novel object. If mice remember the previous objects, they will subsequently spend more time with a novel object 34 . All groups behaved similarly during habituation and the initial exposure, although mice receiving Jq1 for 3 weeks explored less during testing (Supplementary Fig. 7e-g) . Strikingly, while control mice preferred the novel object as expected, Jq1-treated mice showed no preference (Fig. 7c) . However, when mice were tested immediately after the initial exposure, control and Jq1 treated mice performed equally well (Supplementary Fig. 7h-j) , suggesting that Jq1 does not disrupt learning or short-term memory but instead affects long-term memory. To control for possible health issues resulting from long-term treatments, we injected mice with a single dose of Jq1 or DMSO either 6 h before or within 30 min after their initial exposure to objects and tested them the following day. We found no preference for the novel object in mice that received a single dose after training (Fig. 7d) . This suggests that Jq1 given during the process of memory consolidation can block long-term memory formation. The smaller effect observed after a dose given before training may be due to a smaller amount of Jq1 remaining in the brain during the consolidation process several hours later. We also tested a fear-conditioning protocol of three tones paired with shocks to determine the extent of the memory deficits ( Fig. 7e) . All mice learned both the cued conditioning and context-dependent conditioning (Supplementary Fig. 7k,l) , demonstrating that Jq1 did not affect this simple behavior dependent on the amygdala. However, mice given Jq1 for 3 weeks froze more in a new context, suggesting they were less able to distinguish between the training context and a new context. This indicates that the more difficult hippocampus-dependent test of context discrimination may also require BET protein function (Fig. 7f) . Together these data provide in vivo support of our cell-based data demonstrating that Jq1 disrupts the transcriptional responses that are critical to neuronal function.
Jq1 treatment decreases seizure susceptibility
To confirm that Jq1 has similar effects on neurons in vivo as it does in vitro, we examined tissue from mice after behavioral testing. Despite the heterogeneity of cortical tissue, we found either trends or significant decreases in IEGs, Gria1 and GluA1 protein ( Supplementary  Fig. 8a,b) . Long-term decreases in Gria1 and other synaptic proteins (Fig. 3c ) may dampen synaptic strength, which also has implications for other aspects of mouse behavior. We hypothesized that if Jq1 effectively decreases neuronal firing though regulation of synaptic proteins, then Jq1 treatment might decrease seizure susceptibility because seizures result from excess synaptic excitability. We injected adult male mice with Jq1 or DMSO for 1 week and then induced seizures with pentylenetetrazol (PTZ) (50 mg/kg) ( Fig. 8a) , which inhibits GABA A receptors, resulting in increased excitatory activity. Jq1-treated mice showed decreased seizure susceptibility (Fig. 8b) , as measured by a modified Racine scale, which measures both severity of seizure and latency to onset of each seizure stage 35, 36 . In addition, while approximately 30% of control mice died after seizure induction, all Jq1 treated mice survived and recovered faster as measured by a return to normal movement ( Fig. 8c and Supplementary  Fig. 8c,d) . Similar but more variable effects were observed in female mice (Supplementary Fig. 8e,f) .
We also tested the kindling method of seizure induction by giving DMSO or Jq1 1 h before mice receive a subthreshold dose of PTZ 37, 38 . This was repeated every 2 d for 2 weeks, and experimental mice as well as an additional unkindled group were tested again 2 weeks later (Fig. 8d) . Mice typically show increased seizure induction over time as PTZ-induced increases in neuronal firing enhance the strength of neuronal connections, intensifying the response to future doses 37 . Mice are considered kindled if they show enhanced susceptibility that is maintained for several weeks. Jq1 had little effect during initial treatments, possibly because mice had only received a few doses of Jq1. However, on day 30, only the DMSO-treated mice showed kindling as compared to the unkindled group (Fig. 8e-g and Supplementary Fig. 8g,h) . These data indicate that Jq1 treatment has effects on neuronal function in vivo similar to those we observed in vitro and raise the possibility of using BET inhibitors for treatment of epilepsy.
DISCUSSION
Our results demonstrate that Brd4 is expressed throughout the brain and is critical to activity-dependent transcription. Neuronal activity acts through CK2 to increase Brd4 association with chromatin. Brd4 then promotes transcription of critical IEGs and synaptic proteins ( Supplementary Fig. 9 ). We found that Jq1 inhibition of Brd4 and its family members blocked novel object preference, indicating impairments in memory consolidation. In addition, consistent with its effects on synaptic proteins, Jq1 treatment also decreased seizure susceptibility in mice. This is, to our knowledge, the first demonstration that Brd4 has a critical function in neurons and that BET protein inhibition affects memory consolidation.
Implications for the clinical use of BET inhibitors
Our data demonstrate that Brd4 is necessary for rapid activation of genes. As has been demonstrated by many researchers, the first few minutes following a burst of neuronal activity are of critical importance for the activation of an appropriate transcription response in a cell [3] [4] [5] [6] . Loss of this rapid response may represent the mechanism through which Brd4 inhibition prevents long-term memory formation.
BET protein inhibitors have been proposed as a treatment for several types of cancer and are now in clinical trials. Initial mouse studies reported that Jq1 was well tolerated 17, 18, 23, 33 , and we did not find obvious deficits in the health or mobility of mice. However, our study provides new evidence that use of such inhibitors causes memory deficits in mice and thus may also cause neurological problems in patients receiving these drugs. Our results suggest that compounds that do not cross the blood-brain barrier may pose less risk of neurological side effects.
CK2 in neurons CK2 has several established functions in neurons in addition to regulating Brd4. CK2 phosphorylates the GluA1 and GluA2 subunits of the AMPA receptor to promote its expression 27 and regulates the composition of the NMDA receptor 28 . These synaptic actions of CK2 promote synaptic strength, as does the function we propose for CK2 in regulating Brd4. This dual function would allow CK2 to act immediately on the synapse by directly phosphorylating synaptic proteins while also acting through Brd4 to promote expression of these same genes in order to consolidate synaptic changes. The effects of the CK2 inhibitor TBB have also been tested in vivo in an epilepsy model 39 . TBB treatment blocks recurrent epileptiform discharges in hippocampal slice preparations after magnesium removal. We found the Jq1 resulted in decreased seizure susceptibility ( Fig. 7) , suggesting that some of CK2's effects on epileptiform discharges may be the result of its action on Brd4 as well as its effects on the synapse.
BET inhibitors as epilepsy drugs
We found that Jq1 decreased the seizure susceptibility, potentially by decreasing levels of the GluA1 subunit of AMPARs, which have been linked to epilepsy [40] [41] [42] [43] [44] [45] [46] [47] . Decreased levels of other gene targets that regulate synaptic function may also contribute to the seizure effect though mechanisms such as phosphorylation of GluA1 (ref. 48) . Although the dose we tested resulted in memory deficits, it is possible that in an overactive, epileptic brain Jq1 would restore normal levels of synaptic proteins. Most epilepsy treatments directly target synaptic proteins and receptors. Jq1 treatment represents a novel approach by targeting a protein responsible for the transcriptional regulation of these synaptic receptors instead of modifying proteins already present at the synapse. While many cases of epilepsy respond to available treatments, a portion are refractory to existing drugs 38 . It is possible that this approach of targeting transcriptional regulators of synaptic proteins rather than targeting synaptic proteins directly may provide a more robust method of dampening the heightened synaptic activity that leads to seizures and could provide new avenues of treatments for these patients. when comparing multiple groups. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 20, 30, 37 . Data distribution was assumed to be normal, but this was not formally tested. For fear conditioning, two-way ANOVA was performed in R with post hoc Bonferroni corrections for individual comparisons. For novel object testing, context discrimination was calculated by time spent with objects: (novel − familiar)/(novel + familiar). Univariate analysis was used for each individual group to compare to a context discrimination of zero. Degrees of freedom were calculated as the biological replicates minus 1.
For all other behavioral testing, t-tests with a Bonferroni correction were used to compare between multiple groups.
A Supplementary methods checklist is available.
npg
